Jonathan da Costa, MD
Nephrology · Miami, FLNPI 1275890170
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,005 of the $73,551 with a category attached, or 77.5%. Bayer accounts for 64.9% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $29,567, more than ten times the $1,214 reported in 2019. Among nephrology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 566 payments — averaging $129.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$48K
- Akebia Therapeutics Inc$16K
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$2K
- AstraZeneca$1K
- OPKO Pharmaceuticals, LLC$580
- plus $4K from 23 others
Across 3 payments — averaging $2868.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$9K
- Boehringer Ingelheim International GmbH$39
What the payments were for
- Consulting fees$1,5392%
- Speaking & faculty fees$57,00578%
- Travel & lodging$1,4002%
- Food & beverage$13,31818%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 84 | $47,720 |
| Akebia Therapeutics Inc | 65 | $15,887 |
| Amgen(2 entities) | 85 | $2,071 |
| Mallinckrodt Hospital Products Inc. | 86 | $1,808 |
| AstraZeneca | 48 | $1,249 |
| OPKO Pharmaceuticals, LLC | 27 | $580 |
| Aurinia Pharma U.S., Inc. | 29 | $554 |
| Calliditas Therapeutics US Inc. | 20 | $406 |
| Travere Therapeutics, Inc. | 17 | $404 |
| Otsuka America Pharmaceutical, Inc. | 15 | $322 |
| Vifor Pharma, Inc. | 12 | $296 |
| Scpharmaceuticals Inc. | 6 | $276 |
| Mallinckrodt Enterprises LLC | 5 | $276 |
| Novartis | 12 | $259 |
| Boehringer Ingelheim | 9 | $237 |
| ANI Pharmaceuticals, Inc. | 7 | $192 |
| Fresenius USA Marketing, Inc. | 9 | $190 |
| GSK | 6 | $150 |
| Lilly USA, LLC | 4 | $140 |
| Ardelyx, Inc. | 5 | $121 |
| Nxstage Medical, Inc. | 2 | $119 |
| Kyowa Kirin, Inc. | 3 | $79 |
| Novo Nordisk | 4 | $78 |
| Mannkind Corporation | 1 | $40 |
| One Lambda, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,551 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 217 | $174,087 |
| JardianceEmpagliflozin | 159 | $130,087 |
| FarxigaDapagliflozin Propanediol | 128 | $96,634 |
| MounjaroTirzepatide | 58 | $61,448 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $26,599 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $17,487 |
| OzempicSemaglutide | 15 | $14,017 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $8,906 |
| Sevelamer Carbonate | 15 | $2,043 |
| Nifedipine ErNifedipine | 33 | $901 |
| Irbesartan | 42 | $593 |
| Mycophenolate Mofetil | 11 | $562 |
| Labetalol Hcl | 19 | $319 |
| Chlorthalidone | 34 | $262 |
| Cinacalcet Hcl | 13 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $47,720 | $174,087217 claims |
| Boehringer IngelheimJardiance | $237 | $130,087159 claims |
| AstraZenecaFarxiga, Lokelma | $1,249 | $114,120151 claims |
| Lilly USA, LLCMounjaro | $140 | $61,44858 claims |
| Novo NordiskOzempic | $78 | $14,01715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.
Other nephrology in Miami
- Gabriel ContrerasMiami$133K
- Alessia FornoniMiami$97K
- Yelena DrexlerMiami$43K
- Jochen ReiserMiami$43K
- Alba Gonzalez-OchoaMiami$39K
- Jorge BusseMiami$28K
- Loay SalmanMiami$14K
- David RothMiami$12K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.